Influence of antecedent Glivec® therapy (imatinib mesylate) on allogeneic stem cell transplantation outcome in CML Ph+ and ALL Ph+ patients -: single-centre experience

被引：0
|
作者：
Holowiecki, J [1 ]
Kruzel, T [1 ]
Wojnar, J [1 ]
Krawczyk-Kulis, M [1 ]
Wylezol, I [1 ]
机构：
[1] L Warynski Silesian Med Acad, Katowice, Poland
来源：
BONE MARROW TRANSPLANTATION | 2004年 / 33卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S138 / S138
页数：1
相关论文
共 50 条
  • [41] Allogeneic haematopoietic stem cell transplantation for metabolic disorders, a single-centre experience
    Ringden, O
    Remberger, M
    Svahn, B
    Barkholt, L
    Aschan, J
    Mattsson, J
    Le Blanc, K
    Gustafsson, B
    Hassan, Z
    Svenberg, P
    Solders, G
    von Dobeln, U
    Winiarski, J
    Ljungman, P
    Malm, G
    BONE MARROW TRANSPLANTATION, 2005, 35 : S267 - S267
  • [42] Allogeneic stem cell transplantation for chronic lymphocytic leukaemia: a single-centre experience
    Valkova, V.
    Vitek, A.
    Pohlreich, D.
    Markova, M.
    Schwarz, J.
    Cetkovsky, P.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S307 - S308
  • [43] Feasibility and toxicity of nommyeloablative hematopoietic cell transplantation (HCT) with or without imatinib for Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL).
    Norasetthada, L
    Maris, MB
    Sandmaier, BM
    Maloney, DG
    Georges, G
    Druker, B
    Radich, J
    Storb, R
    BLOOD, 2004, 104 (11) : 346B - 347B
  • [44] Outcome of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) after allogeneic hematopoietic stem cell transplantation (HSCT):: Results from the French Bone Marrow Transplantation Society (SFGM).
    Espérou, H
    Tanguy, ML
    Boiron, JM
    Jouet, JP
    Kuentz, M
    Bordigoni, P
    Cahn, JY
    Michallet, M
    Baruchel, A
    Dombret, H
    Milpied, N
    BLOOD, 2000, 96 (11) : 198A - 198A
  • [45] The effect of Gleevec (STI571;imatinib mesylate) in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) with secondary chromosomal aberrations.
    Mohamed, AN
    Pemberton, P
    Zonder, JA
    Homisha, S
    Ford, J
    Schiffer, CA
    BLOOD, 2001, 98 (11) : 560A - 560A
  • [46] Second allogeneic stem cell transplantation for relapsed leukaemias: a single-centre outcome study
    Schade, H.
    Humpe, A.
    Guenther, A.
    Schrauder, A.
    Valerius, T.
    Gramatzki, M.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S89 - S90
  • [47] Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML
    M Weisser
    C Schmid
    C Schoch
    W Hiddemann
    H J Kolb
    Bone Marrow Transplantation, 2005, 36 : 1017 - 1018
  • [48] Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML
    Weisser, M
    Schmid, C
    Schoch, C
    Hiddemann, W
    Kolb, HJ
    BONE MARROW TRANSPLANTATION, 2005, 36 (11) : 1017 - 1018
  • [49] Allogeneic stem cell transplantation for acute leukaemia in advanced phase: a single-centre experience
    Bittencourt, H
    Lodi, F
    Delgado, R
    Borges, L
    Coutinho, M
    Weira, A
    Veloso, G
    Morais, R
    Pereira, A
    Faria, B
    BONE MARROW TRANSPLANTATION, 2006, 37 : S124 - S124
  • [50] Allogeneic stem cell transplantation as treatment of marrow failure syndromes: a single-centre experience
    Cerrato, C.
    Martin, C.
    Rodriguez, G.
    Tallon, J. D.
    Matin, V.
    Roman, J.
    Fernandez, N.
    Labrador, M.
    Molina, J. R.
    Rojas, R.
    Martinez, F.
    Gomez, P.
    Torres-Gomez, A.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S376 - S377
12345